{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:55:37Z","timestamp":1788188137929,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00520-022-07257-2","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:02:53Z","timestamp":1656572573000},"page":"8051-8058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Marina K.","family":"Ibraheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Parseghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"7257_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D et al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15\u201331","journal-title":"Expert Opin Ther Targets"},{"key":"7257_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371821","volume":"1","author":"G Fabbrocini","year":"2015","unstructured":"Fabbrocini G, Panariello L, Caro G, Cacciapuoti S (2015) Acneiform rash induced by EGFR Inhibitors: review of the literature and new insights. Skin Appendage Disord 1:31\u201337","journal-title":"Skin Appendage Disord"},{"key":"7257_CR3","doi-asserted-by":"publisher","unstructured":"Solassol I, Pinguet F, Quantin X (2019) FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules 9. https:\/\/doi.org\/10.3390\/biom9110668","DOI":"10.3390\/biom9110668"},{"key":"7257_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1677\/erc.1.00600","volume":"11","author":"PM Harari","year":"2004","unstructured":"Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689\u2013708","journal-title":"Endocr Relat Cancer"},{"key":"7257_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","volume":"20","author":"H Modjtahedi","year":"2009","unstructured":"Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20:851\u2013855","journal-title":"Anticancer Drugs"},{"key":"7257_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J et al (2013) An epithelial\u2013mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19:279\u2013290","journal-title":"Clin Cancer Res"},{"key":"7257_CR7","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1158\/1535-7163.MCT-12-0195","volume":"11","author":"T Nakagawa","year":"2012","unstructured":"Nakagawa T, Takeuchi S, Yamada T et al (2012) Combined therapy with mutant-selective EGFR inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11:2149\u20132157","journal-title":"Mol Cancer Ther"},{"key":"7257_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 8:428\u2013443","journal-title":"Cancer Discov"},{"key":"7257_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","volume":"28","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Ribas A, Larkin J et al (2017) Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 28:1137\u20131144","journal-title":"Ann Oncol"},{"key":"7257_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00520-020-05381-5","volume":"28","author":"M Welborn","year":"2020","unstructured":"Welborn M, Kubicki SL, Garg N, Patel AB (2020) Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Support Care Cancer 28:2499\u20132502","journal-title":"Support Care Cancer"},{"key":"7257_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11912-013-0308-6","volume":"15","author":"VR Belum","year":"2013","unstructured":"Belum VR, Fischer A, Choi JN, Lacouture ME (2013) Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 15:249\u2013259","journal-title":"Curr Oncol Rep"},{"key":"7257_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","volume":"56","author":"JC Hu","year":"2007","unstructured":"Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317\u2013326","journal-title":"J Am Acad Dermatol"},{"key":"7257_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3747\/co.22.2430","volume":"22","author":"B Melosky","year":"2015","unstructured":"Melosky B, Leighl NB, Rothenstein J et al (2015) Management of egfr tki\u2013induced dermatologic adverse events. Curr Oncol 22:123\u2013132","journal-title":"Curr Oncol"},{"key":"7257_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/0019-5154.131398","volume":"59","author":"B Madke","year":"2014","unstructured":"Madke B, Gole P, Kumar P, Khopkar U (2014) Dermatological side effects of epidermal growth factor receptor inhibitors: \u2018PRIDE\u2019 complex. Indian J Dermatol 59:271\u2013274","journal-title":"Indian J Dermatol"},{"key":"7257_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00520-012-1623-4","volume":"21","author":"LI Wagner","year":"2013","unstructured":"Wagner LI, Berg SR, Gandhi M et al (2013) The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21:1033\u20131041","journal-title":"Support Care Cancer"},{"key":"7257_CR16","doi-asserted-by":"crossref","unstructured":"Steyerberg EW (2019) Applications of prediction models. In: Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating (Steyerberg EW, ed). Cham, Springer International Publishing, 15\u201336","DOI":"10.1007\/978-3-030-16399-0_2"},{"key":"7257_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017:147.\u00a0https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 28 June 2022"},{"key":"7257_CR18","doi-asserted-by":"publisher","unstructured":"Holcmann M, Sibilia M (2015) Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2. https:\/\/doi.org\/10.1080\/23723556.2015.1004969","DOI":"10.1080\/23723556.2015.1004969"},{"key":"7257_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ajd.12124","volume":"55","author":"R Anforth","year":"2014","unstructured":"Anforth R, Liu M, Nguyen B et al (2014) Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 55:250\u2013254","journal-title":"Australas J Dermatol"},{"key":"7257_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch","year":"2007","unstructured":"Lynch TJ, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610\u2013621","journal-title":"Oncologist"},{"key":"7257_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847\u2013853","journal-title":"Cancer"},{"key":"7257_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun R-J et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"7257_CR23","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","volume":"7","author":"B Burtness","year":"2009","unstructured":"Burtness B, Anadkat M, Basti S et al (2009) NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 7(Suppl 1):S5-21 (quiz S22-24)","journal-title":"J Natl Compr Canc Netw"},{"key":"7257_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31\u201339","journal-title":"Am J Clin Dermatol"},{"key":"7257_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"7257_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-016-3419-4","volume":"25","author":"B Tischer","year":"2017","unstructured":"Tischer B, Huber R, Kraemer M, Lacouture ME (2017) Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 25:651\u2013660","journal-title":"Support Care Cancer"},{"key":"7257_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","volume":"5","author":"LM Guggina","year":"2017","unstructured":"Guggina LM, Choi AW, Choi JN (2017) EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther 5:135\u2013148","journal-title":"Oncol Ther"},{"key":"7257_CR28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jaad.2019.10.003","volume":"82","author":"ED Andrews","year":"2020","unstructured":"Andrews ED, Garg N, Patel AB (2020) A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor\u2013 and mitogen-activated protein kinase kinase inhibitor\u2013induced acneiform eruptions. J Am Acad Dermatol 82:998\u20131000","journal-title":"J Am Acad Dermatol"},{"key":"7257_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","volume":"153","author":"R Gutzmer","year":"2005","unstructured":"Gutzmer R, Werfel T, Mao R et al (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153:849\u2013851","journal-title":"Br J Dermatol"},{"key":"7257_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2340\/00015555-0330","volume":"88","author":"P Vezzoli","year":"2008","unstructured":"Vezzoli P, Marzano AV, Onida F et al (2008) Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol 88:84\u201386","journal-title":"Acta Derm Venereol"},{"key":"7257_CR31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1097\/JTO.0b013e3181ec1729","volume":"5","author":"P Bidoli","year":"2010","unstructured":"Bidoli P, Cortinovis DL, Colombo I et al (2010) Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol 5:1662\u20131663","journal-title":"J Thorac Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07257-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:18:50Z","timestamp":1664183930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07257-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7257"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07257-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional IRB approved protocol PA15-0959.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Waiver of consent obtained from institutional IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable\u2014only aggregate data presented.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}